Savara Inc.

NasdaqGS SVRA

Savara Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 126.31 M

Savara Inc. Net Cash Used Provided By Financing Activities is USD 126.31 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 68.68% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Savara Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 74.89 M, a 81,297.83% change year over year.
Savara Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 92.00 K, a -99.92% change year over year.
Savara Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 120.80 M, a 378.38% change year over year.
Savara Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 25.25 M, a -34.84% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: SVRA

Savara Inc.

CEO	Mr. Matthew Pauls J.D., M.B.A.
IPO Date	April 28, 2017
Location	United States
Headquarters	Building III
Employees	37
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Key trends

Past 5 years